Home › Funds › Madison Avenue Partners, LP › LKFT
Madison Avenue Partners, LP position in LKFT
LAKEFRONT BIOTHERAPEUTICS NV
Madison Avenue Partners, LP reported holding 3,447,807 shares of LKFT (LAKEFRONT BIOTHERAPEUTICS NV) in its Q2 2026 13F filing — a position valued at US$103.4M, representing 4.45% of its reported portfolio and ranking #10 among its reported holdings. Madison Avenue Partners, LP has disclosed LKFT holdings in 5 of the last 5 reported quarters, going back to Q2 2025.
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
How Madison Avenue Partners, LP's LKFT position evolved
Madison Avenue Partners, LP first disclosed a stake in LKFT in Q2 2025 at 1,877,011 shares (US$52.5M). The position peaked in Q2 2026 at 3,447,807 shares, worth US$103.4M. Across 5 filings, Madison Avenue Partners, LP increased the stake 4 time(s), trimmed it 0 time(s) and left it unchanged 0 time(s). The most recent filing (Q2 2026) shows 3,447,807 shares valued at US$103.4M — an increase of 982,628 shares quarter over quarter.. Notable position changes include a 40% increase in Q2 2026 (shares fell 1% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q2 2025 | 1.88M | $52.54M | New |
| Q3 2025 | 2.20M | $76.06M | Add |
| Q4 2025 | 2.21M | $72.37M | Add |
| Q1 2026 | 2.47M | $73.96M | Add |
| Q2 2026 | 3.45M | $103.37M | Add |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About LKFT and 13F data
LKFT (LAKEFRONT BIOTHERAPEUTICS NV) is a company whose sector is not yet classified in our data. 17 other funds we track also report a position in LKFT — the largest reported positions include GILEAD SCIENCES, INC. (US$500.2M), TANG CAPITAL MANAGEMENT LLC (US$113.5M), Prosight Management, LP (US$61.3M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding LKFT
- GILEAD SCIENCES, INC. 16.71M sh · $500.16M · Q2 2026
- TANG CAPITAL MANAGEMENT LLC 3.79M sh · $113.50M · Q2 2026
- Prosight Management, LP 2.04M sh · $61.26M · Q2 2026
- EcoR1 Capital, LLC 1.67M sh · $49.98M · Q2 2026
- DME Capital Management, LP 482.75K sh · $14.47M · Q2 2026
- DAFNA Capital Management LLC 130.18K sh · $3.90M · Q2 2026
More on Madison Avenue Partners, LP
FAQ
How long has Madison Avenue Partners, LP held LKFT?
Madison Avenue Partners, LP has disclosed LKFT holdings in 5 of the last 5 reported quarters, going back to Q2 2025.
What is Madison Avenue Partners, LP's current position in LKFT?
As of Q2 2026, Madison Avenue Partners, LP holds 3.45M shares of LKFT (LAKEFRONT BIOTHERAPEUTICS NV), valued at $103.37M, representing 4.45% of its reported portfolio and ranking #10.
Has Madison Avenue Partners, LP been buying or selling LKFT?
In the latest 13F filing (Q2 2026), Madison Avenue Partners, LP increased its position in LKFT. The position peaked in Q2 2026 at 3.45M shares.
Which other funds hold LKFT?
Other major institutional holders of LKFT include GILEAD SCIENCES, INC., TANG CAPITAL MANAGEMENT LLC, Prosight Management, LP, among 17 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.